• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Konidaris Tasos

    11/9/21 5:36:52 PM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Konidaris Tasos

    (Last) (First) (Middle)
    C/O KADMON HOLDINGS, INC.
    450 E. 29TH STREET

    (Street)
    NEW YORK NY 10016

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Kadmon Holdings, Inc. [ KDMN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/09/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $4.12 11/09/2021 D 50,000 (1) 06/29/2027 Common Stock, par value $0.001 50,000 $5.38(2) 0 D
    Stock Option (right to buy) $3.35 11/09/2021 D 50,000 (1) 07/27/2028 Common Stock, par value $0.001 50,000 $6.15(2) 0 D
    Stock Option (right to buy) $2.29 11/09/2021 D 100,000 (1) 05/15/2029 Common Stock, par value $0.001 100,000 $7.21(2) 0 D
    Stock Option (right to buy) $4.44 11/09/2021 D 102,040 (1) 05/13/2030 Common Stock, par value $0.001 102,040 $5.06(2) 0 D
    Stock Option (right to buy) $3.58 11/09/2021 D 116,370 (1) 05/12/2031 Common Stock, par value $0.001 116,370 $5.92(2) 0 D
    Explanation of Responses:
    1. In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
    2. Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
    /s/ Gregory S. Moss, Attorney-in-Fact 11/09/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings

    $KDMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

      Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -

      5/1/23 6:00:00 AM ET
      $MGTX
      $OVID
      $KDMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:38 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Cohen David E

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:37:34 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Ryan John L

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:04 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Financials

    Live finance-specific insights

    See more
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p

      8/5/21 4:05:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to

      5/6/21 4:01:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    SEC Filings

    See more

    $KDMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 15-12B filed by Kadmon Holdings, Inc.

      15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/19/21 4:01:10 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:18 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:09 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Holdings downgraded by Mizuho with a new price target

      Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously

      9/14/21 7:13:20 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Holdings downgraded by Jefferies with a new price target

      Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously

      9/9/21 5:30:28 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Oppenheimer reiterated coverage on Kadmon Holdings with a new price target

      Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      7/19/21 7:45:32 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

      NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c

      3/1/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Kadmon Holdings, Inc.

      SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)

      9/17/21 8:24:15 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Kadmon Holdings, Inc. (Amendment)

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      5/28/21 5:04:26 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      2/17/21 3:12:07 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care